NCT07484022 2026-03-19Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerGenerate BiomedicinesPhase 1 Not yet recruiting37 enrolled
NCT06405542 2026-03-16EX-CIPNUniversity Health Network, TorontoPhase 1 Active not recruiting40 enrolled